Self-screen has a long history and track record in translational HPV related science. The company was founded in 2008 to advance the implementation of scientific discoveries in the field of HPV related cancer screening into routine practice. Our dedication is towards the development and clinical application of molecular assays for the early detection of anogenital (pre)cancers, to the benefit of patients and health care programs around the world.

Currently, the company’s main focus is on cervical (pre)cancer screening and prevention. Self-screen has two clinically validated molecular assays on the market. We strive towards full-molecular screening to ensure sensitivity, objectivity, reproducibility and high-throughput possibilities. Our research and development pipeline focuses on extension towards other sample types, such as self-collected specimens or urine, various platforms as well as towards other cancer types.